NCT00000779View on ClinicalTrials.gov

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

PHASE1CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

Not specified

Study Completion Date

September 30, 1996

Conditions
HIV Infections
Interventions
BIOLOGICAL

Aluminum hydroxide

BIOLOGICAL

MF59

BIOLOGICAL

rgp120/HIV-1IIIB

BIOLOGICAL

rgp120/HIV-1MN

BIOLOGICAL

rgp120/HIV-1 SF-2

BIOLOGICAL

Env 2-3

Trial Locations (10)

10016

NY Univ. HIV/AIDS CRS, New York

80262

University of Colorado Hospital CRS, Aurora

94115

Stanford CRS, Palo Alto

943055107

San Mateo County AIDS Program, San Mateo

951282699

Santa Clara Valley Med. Ctr., San Jose

981224304

University of Washington AIDS CRS, Seattle

Unknown

UCLA CARE Center CRS, Los Angeles

02114

Massachusetts General Hospital ACTG CRS, Boston

02118

Bmc Actg Crs, Boston

02215

Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000779 - A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3 | Biotech Hunter | Biotech Hunter